Relay Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Relay Therapeutics Inc RLAY.OQ reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -63 cents. The mean expectation of eleven analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -51 cents to -32 cents per share.

• Reported revenue was zero​; analysts expected $4.97 million.

• Relay Therapeutics Inc's reported EPS for the quarter was a loss of 43 cents​.

• The company reported a quarterly loss of $74.15 million.

• Relay Therapeutics Inc shares had risen by 9.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.2% in the last three months.​

• In the last 30 days, five analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Relay Therapeutics Inc is $14.00, about 34.6% above its last closing price of $9.16

This summary was machine generated from LSEG data February 26 at 11:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)